SILVERARC CAPITAL MANAGEMENT, LLC
Position in SYRE — Spyre Therapeutics, Inc.
CIK 1816307
BOSTON, MA
Position in SYRE
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$5,323,160
-$4,089,851 QoQ
Shares Held
59,959
-67.9% QoQ
Ownership
0.068%
of shares outstanding
% of Portfolio
0.59%
of 13F equity value
Holder Rank
#93
of 266 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in SYRE Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026SILVERARC CAPITAL MANAGEMENT, LLC holds $802,586,993 across 53 Biotechnology names. SYRE ranks #37 (0.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ASND |
Ascendis Pharma A/S
|
206,234 | $55,006,732 | |
| 2 | CELC |
Celcuity Inc.
|
500,996 | $52,414,201 | |
| 3 | COGT |
Cogent Biosciences, Inc.
|
1,280,707 | $49,563,360 | |
| 4 | URGN |
UroGen Pharma Ltd.
|
1,301,979 | $47,912,827 | |
| 5 | IMNM |
Immunome Inc.
|
2,017,009 | $42,740,420 | |
| 6 | DNTH |
Dianthus Therapeutics, Inc. /DE/
|
390,000 | $38,017,200 | |
| 7 | RYTM |
Rhythm Pharmaceuticals, Inc.
|
311,461 | $34,581,514 | |
| 8 | ORKA |
Oruka Therapeutics, Inc.
|
352,802 | $33,576,166 |
All Filings in SYRE
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $5,323,160 | 59,959 | Shares | Sole | 2026-08-13 | |
| 2026-03-31 | $9,413,011 | 186,618 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $6,150,264 | 187,737 | Shares | Sole | 2026-02-12 | |
| No filing history on record for this holder in this stock. | ||||||